Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)
You may also be interested in...
Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S
Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S
China Delays Implementation Of Essential Drugs List; Analysts Say List Has Less Impact Than Earlier Predicted
SHANGHAI - China's Ministry Of Health announced it will delay implementation of the Essential Drug List in 30 percent of government-controlled clinics until the end of March